Filing Flows › Vanda Pharmaceuticals (VNDA) › PONVORY® net product sales revenue
Vanda Pharmaceuticals (VNDA) PONVORY® net product sales revenue by quarter
Vanda Pharmaceuticals' PONVORY® net product sales revenue was $7.7M in Q3 2026 (third quarter 2026), -2% from Q2 2026. Over the last 7 quarters it ranged from $5.6M (Q1 2025) to $7.9M (Q2 2026).
| Quarter | PONVORY® net product sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $7.7M | -2% | +10% |
| Q2 2026 | $7.9M | +28% | +12% |
| Q1 2026 | $6.2M | -18% | +10% |
| Q4 2025 | $7.6M | +8% | — |
| Q3 2025 | $7.0M | -1% | — |
| Q2 2025 | $7.1M | +26% | — |
| Q1 2025 | $5.6M | — | — |
Q3 2026 at a glance
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vanda Pharmaceuticals' PONVORY® net product sales revenue?
Vanda Pharmaceuticals' PONVORY® net product sales revenue was $7.7M in Q3 2026 (third quarter 2026), -2% from Q2 2026.
How has Vanda Pharmaceuticals' PONVORY® net product sales revenue changed?
Over the last 7 quarters it ranged from $5.6M (Q1 2025) to $7.9M (Q2 2026).